New COVID-19 Immunity Study Finds Majority of Coronavirus-Infected People Retain Antibodies for Over Six Months
|
By HospiMedica International staff writers Posted on 22 Dec 2020 |

Illustration
A new COVID-19 immunity study has found that a very large share of people infected with coronavirus in the spring still had detectable antibodies six months later.
The study by the Finnish Institute for Health and Welfare (THL; Helsinki, Finland) aimed to find out how long the antibodies last in SARS CoV2 virus infected persons, and thus also to assess the duration of possible protection. A previous study by THL and the City of Helsinki had found that nearly all those infected with coronavirus (63/64) formed antibodies, which also remained for a period of four months in most of the participants.
The follow-up study for the serological population study of the coronavirus epidemic began in October. People aged 18 or over, who had a coronavirus infection confirmed by PCR-testing in the spring at least six months prior, were invited to take part in the study. The first blood samples were taken in early November. To date, 1,164 subjects from five different hospital districts have participated in the study. A microneutralization test developed at THL was utilized in the antibody study. The microneutralization test measures antibodies that neutralize the virus. Thus far, these antibodies have been found in 792/867 subjects (91%) in the follow-up study. The THL study found neutralizing antibodies in all 129 COVID-19 patients who had been hospitalized.
Other recent studies have also shown that neutralizing antibodies persist in a large proportion of those infected, despite a decrease in total antibodies in the months following infection. Coronaviruses that cause severe infections, such as SARS and MERS, can produce antibodies that persist for several years. The neutralizing antibodies formed in infected persons are likely to provide protection against symptoms or severe symptoms of a new infection, as evidenced by animal experiments. However, it is not yet known which amount of antibodies is sufficient to protect a person from an infection or how long the protection will last.
"The fact that antibodies persist in such a large proportion of those infected for a long time is a promising finding, and, in particular, the persistence of neutralizing antibodies can mean longer-term protection from new infection," said THL's Research Manager Merit Melin.
"Our observation that neutralizing antibodies persist in most people for more than six months after infection also increases optimism about the long-term protection provided by vaccines," added THL's Research Manager Arto Palmu.
Related Links:
Finnish Institute for Health and Welfare (THL)
The study by the Finnish Institute for Health and Welfare (THL; Helsinki, Finland) aimed to find out how long the antibodies last in SARS CoV2 virus infected persons, and thus also to assess the duration of possible protection. A previous study by THL and the City of Helsinki had found that nearly all those infected with coronavirus (63/64) formed antibodies, which also remained for a period of four months in most of the participants.
The follow-up study for the serological population study of the coronavirus epidemic began in October. People aged 18 or over, who had a coronavirus infection confirmed by PCR-testing in the spring at least six months prior, were invited to take part in the study. The first blood samples were taken in early November. To date, 1,164 subjects from five different hospital districts have participated in the study. A microneutralization test developed at THL was utilized in the antibody study. The microneutralization test measures antibodies that neutralize the virus. Thus far, these antibodies have been found in 792/867 subjects (91%) in the follow-up study. The THL study found neutralizing antibodies in all 129 COVID-19 patients who had been hospitalized.
Other recent studies have also shown that neutralizing antibodies persist in a large proportion of those infected, despite a decrease in total antibodies in the months following infection. Coronaviruses that cause severe infections, such as SARS and MERS, can produce antibodies that persist for several years. The neutralizing antibodies formed in infected persons are likely to provide protection against symptoms or severe symptoms of a new infection, as evidenced by animal experiments. However, it is not yet known which amount of antibodies is sufficient to protect a person from an infection or how long the protection will last.
"The fact that antibodies persist in such a large proportion of those infected for a long time is a promising finding, and, in particular, the persistence of neutralizing antibodies can mean longer-term protection from new infection," said THL's Research Manager Merit Melin.
"Our observation that neutralizing antibodies persist in most people for more than six months after infection also increases optimism about the long-term protection provided by vaccines," added THL's Research Manager Arto Palmu.
Related Links:
Finnish Institute for Health and Welfare (THL)
Latest COVID-19 News
- Low-Cost System Detects SARS-CoV-2 Virus in Hospital Air Using High-Tech Bubbles
- World's First Inhalable COVID-19 Vaccine Approved in China
- COVID-19 Vaccine Patch Fights SARS-CoV-2 Variants Better than Needles
- Blood Viscosity Testing Can Predict Risk of Death in Hospitalized COVID-19 Patients
- ‘Covid Computer’ Uses AI to Detect COVID-19 from Chest CT Scans
- MRI Lung-Imaging Technique Shows Cause of Long-COVID Symptoms
- Chest CT Scans of COVID-19 Patients Could Help Distinguish Between SARS-CoV-2 Variants
- Specialized MRI Detects Lung Abnormalities in Non-Hospitalized Long COVID Patients
- AI Algorithm Identifies Hospitalized Patients at Highest Risk of Dying From COVID-19
- Sweat Sensor Detects Key Biomarkers That Provide Early Warning of COVID-19 and Flu
- Study Assesses Impact of COVID-19 on Ventilation/Perfusion Scintigraphy
- CT Imaging Study Finds Vaccination Reduces Risk of COVID-19 Associated Pulmonary Embolism
- Third Day in Hospital a ‘Tipping Point’ in Severity of COVID-19 Pneumonia
- Longer Interval Between COVID-19 Vaccines Generates Up to Nine Times as Many Antibodies
- AI Model for Monitoring COVID-19 Predicts Mortality Within First 30 Days of Admission
- AI Predicts COVID Prognosis at Near-Expert Level Based Off CT Scans
Channels
Artificial Intelligence
view channelAI Analysis of Pericardial Fat Refines Long-Term Heart Disease Risk
Accurately identifying long-term cardiovascular disease risk in asymptomatic adults remains challenging for clinicians. Missed or underestimated risk delays preventive therapy and increases the chance... Read more
Machine Learning Approach Enhances Liver Cancer Risk Stratification
Hepatocellular carcinoma, the most common form of primary liver cancer, is often detected late despite targeted surveillance programs. Current screening guidelines emphasize patients with known cirrhosis,... Read moreCritical Care
view channel
Angiography-Based FFR Approach Matches Gold Standard Results Without Wires
Accurately determining whether a coronary stenosis limits blood flow is essential to guide percutaneous coronary intervention, yet wire-based physiologic testing remains underused due to added procedural... Read more
Eye Imaging AI Identifies Elevated Cardiovascular Risk
Many adults at risk for atherosclerotic cardiovascular disease are not identified until they undergo formal primary care assessment. Delayed risk recognition can postpone initiation of statins and lifestyle... Read moreSurgical Techniques
view channel
Fiber-Form Bone Graft Expands Intraoperative Options for Spinal Fusion
Spinal and orthopedic fusion procedures often require bone graft materials that handle predictably and support bone formation. Surgeons face added complexity in difficult anatomy and challenging fusion environments.... Read more
Ultrasound‑Aided Catheter Treatment Cuts Early Collapse in Pulmonary Embolism
Acute pulmonary embolism can cause rapid hemodynamic deterioration and early death in hospitalized and emergency patients. Systemic thrombolysis can dissolve clots but is limited by a high risk of major... Read morePatient Care
view channel
Wearable Sleep Data Predict Adherence to Pulmonary Rehabilitation
Chronic obstructive pulmonary disease (COPD) is a long-term lung disorder that makes breathing difficult and often disturbs sleep, reducing energy for daily activities. Limited engagement in pulmonary... Read more
Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care
More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read moreHealth IT
view channel
Voice-Driven AI System Enables Structured GI Procedure Documentation
Documentation during gastrointestinal (GI) procedures often competes with real-time clinical decision-making and imposes a significant cognitive burden on physicians. Manual data entry and post-procedure... Read more
EMR-Based Tool Predicts Graft Failure After Kidney Transplant
Kidney transplantation offers patients with end-stage kidney disease longer survival and better quality of life than dialysis, yet graft failure remains a major challenge. Although a successful transplant... Read more
Printable Molecule-Selective Nanoparticles Enable Mass Production of Wearable Biosensors
The future of medicine is likely to focus on the personalization of healthcare—understanding exactly what an individual requires and delivering the appropriate combination of nutrients, metabolites, and... Read moreBusiness
view channel








